Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-25180.11%
operating margin TTM
-27394.89%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -9.80 |
| peg ratio | 0.76 |
| price to book ratio | 7.37 |
| price to sales ratio | 2,183.37 |
| enterprise value multiple | -9.03 |
| price fair value | 7.37 |
profitability ratios | |
|---|---|
| gross profit margin | 38.64% |
| operating profit margin | -27394.89% |
| pretax profit margin | -25196.59% |
| net profit margin | -25180.11% |
| return on assets | -64.31% |
| return on equity | -63.3% |
| return on capital employed | -80.65% |
liquidity ratio | |
|---|---|
| current ratio | 7.38 |
| quick ratio | 7.38 |
| cash ratio | 1.76 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 5,454.72 |
| cash conversion cycle | -5,454.72 |
| receivables turnover | 0.00 |
| payables turnover | 0.07 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.02 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.02 |
| interest coverage | -6,887.86 |
| cash flow to debt ratio | -31.50 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.35 |
| cash per share | 0.65 |
| operating cash flow per share | -0.35 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -31.50 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -701.30 |
Frequently Asked Questions
When was the last time Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported earnings?
Trevi Therapeutics, Inc. (TRVI) published its most recent earnings results on 06-11-2024.
What is Trevi Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Trevi Therapeutics, Inc. (NASDAQ:TRVI)'s trailing twelve months ROE is -63.3%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Trevi Therapeutics, Inc. (TRVI) currently has a ROA of -64.31%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did TRVI's net profit margin stand at?
TRVI reported a profit margin of -25180.11% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is TRVI's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 7.38 in the most recent quarter. The quick ratio stood at 7.38, with a Debt/Eq ratio of 0.02.